307. カナバン病 Canavan disease Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 9 - (DrugBank : 3) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00657748 (ClinicalTrials.gov) | September 2009 | 9/4/2008 | Lithium and Acetate for Canavan Disease | Evaluation of the Tolerance and Efficiency of a Combined Oral Therapy With Lithium and GTA in Patients With Canavan Disease | Canavan Disease;Infantile;Deficiency Disease;Aspartoacylase;Leukodystrophy, Spongiform | Drug: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug) | Assistance Publique - Hôpitaux de Paris | European Leukodystrophy Association;European Leukodystrophy Association | Withdrawn | 1 Year | 15 Years | Both | 0 | Phase 2 | France |
2 | NCT00724802 (ClinicalTrials.gov) | March 2008 | 18/6/2008 | Oral Glyceryl Triacetate (GTA) in Newborns With Canavan | Oral Glyceryl Triacetate (GTA) in Newborns With Canavan | Canavan Disease | Dietary Supplement: GTA (Glyceryl triacetate);Drug: GTA glyceryl triacetate | Shaare Zedek Medical Center | NULL | Recruiting | N/A | 18 Months | Both | 1 | N/A | Israel |